{"id":544618,"date":"2021-05-25T15:10:02","date_gmt":"2021-05-25T15:10:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=544618"},"modified":"2021-05-25T15:10:02","modified_gmt":"2021-05-25T15:10:02","slug":"rheumatoid-arthritis-ra-market-analysis-market-size-trends-epidemiology-leading-companies-and-therapies-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/rheumatoid-arthritis-ra-market-analysis-market-size-trends-epidemiology-leading-companies-and-therapies-delveinsight_544618.html","title":{"rendered":"Rheumatoid Arthritis (RA) Market Analysis, Market Size, Trends, Epidemiology, Leading Companies And Therapies | DelveInsight"},"content":{"rendered":"
\"Rheumatoid<\/a><\/p>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight\u2019s \u201cRheumatoid Arthritis (RA) \u2013 Market Insights, Epidemiology, and Market Forecast-2030\u201d report delivers an in-depth understanding of the Rheumatoid Arthritis (RA), historical and forecasted epidemiology as well as the Rheumatoid Arthritis (RA) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.\n<\/div>\n

DelveInsight has launched a new report on “Rheumatoid Arthritis (RA) -Market Insights, Epidemiology, and Market Forecast-2030<\/strong>”.<\/p>\n

DelveInsight’s “Rheumatoid Arthritis (RA)  – Market Insights, Epidemiology, and Market Forecast-2030<\/strong><\/a>” report delivers an in-depth understanding of the Rheumatoid Arthritis (RA) , historical and forecasted epidemiology as well as the  Rheumatoid Arthritis (RA)  market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

Some of the key facts of the Report:<\/strong><\/p>\n

    \n
  1. \n

    In 2017, the total diagnosed prevalent cases of RA in the 7MM were 3,825,649. <\/p>\n<\/li>\n

  2. \n

    Among the 7MM, the United States accounted for the highest number of diagnosed prevalent cases during the study period (2017–2030)<\/p>\n<\/li>\n

  3. \n

    In the 7MM, the total gender-specific prevalent cases of RA were 1,007,646 for men and 2,818,003 for women, in the year 2017<\/p>\n<\/li>\n<\/ol>\n

    Key benefits of the report:<\/strong><\/p>\n

    1. Rheumatoid Arthritis (RA) market report covers a descriptive overview and comprehensive insight of the Rheumatoid Arthritis (RA)  epidemiology and Rheumatoid Arthritis (RA) market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)<\/p>\n

    2. The Rheumatoid Arthritis (RA) market report provides insights on the current and emerging therapies.<\/p>\n

    3. Rheumatoid Arthritis (RA) market report provides a global historical and forecasted market covering drug outreach in 7MM.<\/p>\n

    4. The Rheumatoid Arthritis (RA) market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Rheumatoid Arthritis (RA) market.<\/p>\n

    Request for sample pages: https:\/\/www.delveinsight.com\/sample-request\/rheumatoid-arthritis-ra-market<\/span><\/a>
    <\/a><\/strong><\/p>\n

    Rheumatoid Arthritis (RA): Overview<\/strong><\/p>\n

    Rheumatoid arthritis is a chronic inflammatory disorder that can affect more than just your joints. In some people, the condition can damage a wide variety of body systems, including the skin, eyes, lungs, heart and blood vessels.<\/p>\n

    An autoimmune disorder, rheumatoid arthritis occurs when your immune system mistakenly attacks your own body’s tissues.<\/p>\n

    Unlike the wear-and-tear damage of osteoarthritis, rheumatoid arthritis affects the lining of your joints, causing a painful swelling that can eventually result in bone erosion and joint deformity.<\/p>\n

    The key players involved in the Rheumatoid Arthritis (RA) market<\/a>:<\/strong><\/p>\n

      \n
    1. \n

      GlaxoSmithKline<\/p>\n<\/li>\n

    2. \n

      MorphoSys\/Novartis<\/p>\n<\/li>\n

    3. \n

      R-Pharm<\/p>\n<\/li>\n

    4. \n

      AstraZeneca <\/p>\n<\/li>\n

    5. \n

      Roche<\/p>\n<\/li>\n

    6. \n

      Pfizer<\/p>\n<\/li>\n<\/ol>\n

      The launch of the emerging therapies is expected to significantly impact the  Rheumatoid Arthritis (RA)  treatment scenario in the upcoming years:-<\/strong><\/p>\n

      Drug covered<\/strong><\/p>\n

        \n
      1. \n

        Otilimab<\/p>\n<\/li>\n

      2. \n

        Ianalumab <\/p>\n<\/li>\n

      3. \n

        Olokizumab<\/p>\n<\/li>\n

      4. \n

        AZD9567<\/p>\n<\/li>\n

      5. \n

        Fenebrutinib PF-06650833, and PF-06651600 (Ritlecitinib)<\/p>\n<\/li>\n<\/ol>\n

        Request a free sample report @https:\/\/www.delveinsight.com\/sample-request\/rheumatoid-arthritis-ra-market<\/span><\/a><\/strong><\/p>\n

        Table of Contents<\/strong><\/p>\n

        1. Report Introduction<\/p>\n

        2. Executive Summary<\/p>\n

        3. SWOT analysis<\/p>\n

        4. Rheumatoid Arthritis (RA) Patient Share (%) Overview at a Glance<\/p>\n

        5. Rheumatoid Arthritis (RA) Market Overview at a Glance<\/p>\n

        6. Rheumatoid Arthritis (RA) Disease Background and Overview<\/p>\n

        7. Rheumatoid Arthritis (RA) Epidemiology and Patient Population<\/p>\n

        8. Country-Specific Patient Population of Rheumatoid Arthritis (RA) <\/p>\n

        9. Rheumatoid Arthritis (RA) Current Treatment and Medical Practices<\/p>\n

        10. Unmet Needs<\/p>\n

        11. Rheumatoid Arthritis (RA) Emerging Therapies<\/p>\n

        12. Rheumatoid Arthritis (RA) Market Outlook<\/p>\n

        13. Country-Wise Rheumatoid Arthritis (RA) Market Analysis (2017–2030)<\/p>\n

        14. Market Access and Reimbursement of Therapies<\/p>\n

        15. Market drivers<\/p>\n

        16. Market barriers<\/p>\n

        17. Appendix<\/p>\n

        18. Rheumatoid Arthritis (RA) Report Methodology<\/p>\n

        19. DelveInsight Capabilities<\/p>\n

        20. Disclaimer<\/p>\n

        21. About DelveInsight<\/p>\n

        Related Reports:<\/strong><\/p>\n

        Rheumatoid Arthritis (RA)- Pipeline Insights, 2021<\/strong><\/p>\n

        “Rheumatoid Arthritis (RA)- Pipeline Insight, 2021” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Rheumatoid Arthritis (RA) market. A detailed picture of the Rheumatoid Arthritis (RA) pipeline landscape is provided, which includes the disease overview and Rheumatoid Arthritis (RA) treatment guidelines.<\/p>\n

        Rheumatoid Arthritis (RA) -Epidemiology Forecast to 2030<\/strong><\/p>\n

        DelveInsight’s ‘Rheumatoid Arthritis (RA) – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Rheumatoid Arthritis (RA){;l epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n

        Media Contact<\/span>
        Company Name:<\/strong>         DelveInsight Business Research LLP<\/a>
        Contact Person:<\/strong> Kritika Rehani
        Email:<\/strong>         Send Email<\/a>
        Phone:<\/strong> 9193216187
        Address:<\/strong>304 S. Jones Blvd #2432
        City:<\/strong> Las Vegas
        State:<\/strong> Nevada
        Country:<\/strong> United States
        Website:<\/strong>         https:\/\/www.delveinsight.com\/<\/a><\/p>\n

        <\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

        DelveInsight Business Research LLP DelveInsight\u2019s \u201cRheumatoid Arthritis (RA) \u2013 Market Insights, Epidemiology, and Market Forecast-2030\u201d report delivers an in-depth understanding of the Rheumatoid Arthritis (RA), historical and forecasted epidemiology as well as the Rheumatoid Arthritis (RA) market trends in the … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-544618","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/544618","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=544618"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/544618\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=544618"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=544618"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=544618"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}